VIVS
VivoSim Labs, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-61/100
Last price
0.19
▼ 0.01 (5.89%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.19
Prev close
0.20
Day high
0.21
Day low
0.19
Volume
839.84K
Market cap
$3.18M
P/E (TTM)
—
52W range
0.19 – 3.54
Day trading desk
Gap from prior close
-2.90%
Prior close 0.20
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
6.84%
0.19 – 0.20
Position in range
0%
Near session low
ATR (14D)
0.02
10.90% of price
Prior day high
0.21
PDH
Prior day low
0.20
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 5.84M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.52%
-11.4%
1M
-32.14%
-33.6%
3M
-76.25%
-79.6%
6M
-87.97%
-102.9%
YTD
-89.50%
-103.5%
1Y
-94.04%
-109.8%
3Y
-98.67%
-180.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VIVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
395.92K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 31, 26 | LIALIN TONY SERGE Officer |
BUY | 10.00K | $2.80K | Direct |
| Jan 27, 26 | STERN ADAM K. Director |
STOCK | 15.00K | $0 | Direct |
| Jan 27, 26 | MURPHY KEITH E Officer and Director |
STOCK | 15.00K | $0 | Direct |
| Jan 27, 26 | GOBEL DAVID Director |
STOCK | 15.00K | $0 | Direct |
| Jan 27, 26 | COHEN DOUGLAS JAY Director |
STOCK | 15.00K | $0 | Direct |
| Jan 27, 26 | MILHOUS ALISON TJOSVOLD Director |
STOCK | 15.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COHEN DOUGLAS JAY |
Director | 20.90K | Stock Award(Grant) |
GOBEL DAVID |
Director | 15.00K | Stock Award(Grant) |
LIALIN TONY SERGE |
Officer | 10.00K | Purchase |
MILHOUS ALISON TJOSVOLD |
Director | 19.90K | Stock Award(Grant) |
MURPHY KEITH E |
Officer and Director | 26.05K | Stock Award(Grant) |
STERN ADAM K. |
Director | 19.90K | Stock Award(Grant) |
Fundamentals
Market cap$3.18M
Enterprise value$1.49M
Revenue (TTM)$112.00K
Gross profit$-4.21M
EBITDA$-11.14M
Net income$-12.34M
EPS (TTM)$-4.47
Free cash flow$-7.58M
Total cash$1.67M
Total debt$316.00K
Book value / share$-0.73
Shares outstanding16.59M
Float14.42M
Short % of float3.41%
Dividend yield0.00%
Beta (5Y)1.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue13.30
EV / EBITDA-0.13
Gross margin0.00%
Operating margin-15327.78%
Profit margin0.00%
Return on equity-343.10%
Return on assets-89.50%
Debt / equity—
Current ratio1.70
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $131.00K | $144.00K | $109.00K | $370.00K | -9.0% |
| Operating revenue | $131.00K | $144.00K | $109.00K | $370.00K | -9.0% |
| Cost of revenue | $0 | $5.00K | $0 | — | -100.0% |
| Gross profit | $131.00K | $139.00K | $109.00K | — | -5.8% |
| Research & development | $4.19M | $5.03M | $5.50M | $8.88M | -16.6% |
| Selling, general & admin | $7.41M | $7.69M | $9.64M | $9.09M | -3.6% |
| Total operating expense | $11.62M | $12.76M | $15.20M | $18.10M | -8.9% |
| Operating income | -$11.49M | -$12.62M | -$15.09M | -$17.73M | +8.9% |
| Net interest income | $255.00K | $130.00K | $405.00K | $454.00K | +96.2% |
| Pre-tax income | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -456.8% |
| Tax provision | $2.00K | $2.00K | $2.00K | $2.00K | 0.0% |
| Net income | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -456.4% |
| Net income to common | -$13.84M | -$2.49M | -$14.67M | -$17.26M | -456.4% |
| Basic EPS | -5.35 | -1.70 | -19.25 | -23.76 | -214.7% |
| Diluted EPS | -5.35 | -1.70 | -19.25 | -23.76 | -214.7% |
| EBIT | -$13.83M | -$2.48M | -$14.67M | -$17.73M | -458.5% |
| EBITDA | -$13.61M | -$2.21M | -$14.39M | -$17.44M | -516.0% |
| Basic shares | 2.59M | 1.46M | 762.08K | 726.09K | +76.8% |
| Diluted shares | 2.59M | 1.46M | 762.08K | 726.09K | +76.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.02M | $11.31M | $2.90M | $15.30M | -55.6% |
| Cash & short-term investments | $5.02M | $11.31M | $2.90M | $16.01M | -55.6% |
| Accounts receivable | $32.00K | $30.00K | $33.00K | $152.00K | +6.7% |
| Inventory | — | $0 | $297.00K | $0 | — |
| Total current assets | $6.63M | $12.13M | $3.94M | $17.05M | -45.4% |
| Property, plant & equipment | $613.00K | $1.29M | $1.97M | $2.61M | -52.3% |
| Total assets | $7.39M | $14.65M | $6.35M | $20.31M | -49.6% |
| Total current liabilities | $2.79M | $3.74M | $1.86M | $3.67M | -25.5% |
| Total debt | $447.00K | $942.00K | $1.39M | $1.80M | -52.5% |
| Total liabilities | $8.48M | $4.16M | $2.75M | $4.98M | +104.1% |
| Retained earnings | -$356.00M | -$342.16M | -$339.67M | -$325.00M | -4.0% |
| Shareholder equity | -$1.10M | $10.49M | $3.60M | $15.33M | -110.5% |
| Working capital | $3.84M | $8.39M | $2.08M | $13.38M | -54.2% |
| Net tangible assets | -$1.10M | $10.49M | $3.60M | $15.33M | -110.5% |
| Shares issued | 2.89M | 1.90M | 839.81K | 726.41K | +52.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$13.84M | -$2.49M | -$14.67M | -$17.26M | — | -456.4% |
| Depreciation & amortisation | $215.00K | $266.00K | $280.00K | $293.00K | — | -19.2% |
| Stock-based compensation | $303.00K | $532.00K | $1.51M | $2.38M | — | -43.0% |
| Change in working capital | -$695.00K | $1.04M | -$2.02M | $2.31M | — | -167.0% |
| Operating cash flow | -$10.83M | -$9.46M | -$14.65M | -$12.41M | — | -14.4% |
| Capital expenditure | — | -$13.00K | -$42.00K | -$396.00K | -$409.00K | — |
| Investing cash flow | $94.00K | $9.03M | $816.00K | -$966.00K | — | -99.0% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | $4.45M | $8.85M | $1.44M | $0 | — | -49.8% |
| Free cash flow | -$10.83M | -$9.47M | -$14.70M | -$12.80M | — | -14.3% |
| End cash position | $5.17M | $11.46M | $3.04M | $15.44M | — | -54.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $18.00K | $40.00K | $26.00K | $28.00K | $37.00K | — | -55.0% |
| Operating revenue | $18.00K | $40.00K | $26.00K | $28.00K | $37.00K | — | -55.0% |
| Cost of revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | — | $40.00K | $26.00K | $28.00K | $37.00K | $51.00K | — |
| Research & development | $1.13M | $1.13M | $1.14M | $923.00K | $1.00M | — | +0.6% |
| Selling, general & admin | $1.64M | $2.10M | $1.63M | $1.74M | $1.95M | — | -21.8% |
| Total operating expense | $2.78M | $3.23M | $2.78M | $2.66M | $2.95M | — | -13.9% |
| Operating income | -$2.76M | -$3.19M | -$2.75M | -$2.63M | -$2.92M | — | +13.4% |
| Net interest income | $24.00K | $32.00K | $59.00K | $92.00K | $72.00K | — | -25.0% |
| Pre-tax income | -$1.33M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | — | +76.8% |
| Tax provision | $3.00K | $0 | $0 | $2.00K | $0 | — | — |
| Net income | -$1.34M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | — | +76.8% |
| Net income to common | -$1.34M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | — | +76.8% |
| Basic EPS | -0.25 | — | -1.03 | -0.98 | -1.14 | — | — |
| Diluted EPS | -0.25 | — | -1.03 | -0.98 | -1.14 | — | — |
| EBIT | -$1.33M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | — | +76.9% |
| EBITDA | -$1.29M | -$5.72M | -$2.63M | -$2.48M | -$2.78M | — | +77.4% |
| Basic shares | 3.19M | — | 2.61M | 2.60M | 2.49M | — | — |
| Diluted shares | 3.19M | — | 2.61M | 2.60M | 2.49M | — | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.67M | $5.02M | $4.29M | $6.68M | $9.05M | — | -66.8% |
| Cash & short-term investments | $1.67M | $5.02M | $4.29M | $6.68M | $9.05M | — | -66.8% |
| Accounts receivable | $29.00K | $32.00K | $33.00K | $32.00K | $32.00K | — | -9.4% |
| Inventory | — | — | — | — | — | $0 | — |
| Total current assets | $3.23M | $6.63M | $6.04M | $7.59M | $9.68M | — | -51.3% |
| Property, plant & equipment | $476.00K | $613.00K | $773.00K | $941.00K | $1.11M | — | -22.3% |
| Total assets | $3.85M | $7.39M | $6.96M | $9.69M | $11.98M | — | -47.9% |
| Total current liabilities | $1.89M | $2.79M | $2.48M | $2.45M | $2.14M | — | -32.0% |
| Total debt | $316.00K | $447.00K | $577.00K | $700.00K | $822.00K | — | -29.3% |
| Total liabilities | $6.19M | $8.48M | $2.52M | $2.62M | $2.44M | — | -27.0% |
| Retained earnings | -$357.34M | -$356.00M | -$350.24M | -$347.55M | -$345.00M | — | -0.4% |
| Shareholder equity | -$2.35M | -$1.10M | $4.44M | $7.07M | $9.54M | — | -113.5% |
| Working capital | $1.33M | $3.84M | $3.57M | $5.14M | $7.54M | — | -65.3% |
| Net tangible assets | -$2.35M | -$1.10M | $4.44M | $7.07M | $9.54M | — | -113.5% |
| Shares issued | 3.19M | 2.89M | 2.61M | 2.61M | 2.60M | — | +10.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.34M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | +76.8% |
| Depreciation & amortisation | $40.00K | $43.00K | $52.00K | $59.00K | $61.00K | -7.0% |
| Stock-based compensation | $91.00K | $86.00K | $67.00K | $72.00K | $78.00K | +5.8% |
| Change in working capital | -$724.00K | $535.00K | $188.00K | -$74.00K | -$1.34M | -235.3% |
| Operating cash flow | -$3.21M | -$2.24M | -$2.27M | -$2.38M | -$3.94M | -43.6% |
| Capital expenditure | -$23.00K | — | — | — | — | — |
| Investing cash flow | -$23.00K | $94.00K | $0 | $0 | $0 | -124.5% |
| Financing cash flow | -$118.00K | $2.88M | -$118.00K | $0 | $1.68M | -104.1% |
| Free cash flow | -$3.24M | -$2.24M | -$2.27M | -$2.38M | -$3.94M | -44.6% |
| End cash position | $1.81M | $5.17M | $4.43M | $6.82M | $9.20M | -64.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders2.67%
Held by institutions11.09%
Institutions holding26
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.21
-9.09% from price
SMA 20
0.23
-18.98% from price
SMA 50
0.28
-33.00% from price
SMA 100
0.65
-70.67% from price
SMA 200
1.23
-84.52% from price
EMA 12
0.21
-11.51% from price
EMA 26
0.25
-23.34% from price
EMA 50
0.35
-45.66% from price
RSI (14)
27.9
Oversold
MACD (12,26,9)
-0.03
Hist 0.00
ATR (14)
0.02
10.90% of price
Realised vol 30D
68.7%
Annualised
Bollinger upper
0.30
20, 2σ
Bollinger lower
0.17
20, 2σ
50 / 200 cross
Death
0.28 vs 1.23
Trend bias
Below 200
-84.52%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.43
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
68.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-94.3%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.02
10.90% of price
Beta (reported)
1.49
5Y monthly, from filing
Short interest
Shares short
564.68K
Prior 751.42K
Change vs prior
-24.9%
Shorts covering
% of float
3.41%
Normal
% of shares out
3.40%
Against total outstanding
Days to cover
0.8
Liquid
Float
14.42M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateAug 19, 2020
Last split1:12
Split dateMar 21, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Corporate Changes & Voting Matters
8-K · 2026-08-21
Proxy Statements
PRER14A · 2026-08-13
Periodic Financial Reports
10-Q · 2026-08-12
Proxy Statements
PRE 14A · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-06
Offering Registrations
S-1 · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-30
Headlines
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
GlobeNewswire · 24h ago
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
GlobeNewswire · 22d ago
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
GlobeNewswire · 37d ago
VivoSim: Fiscal Q1 Earnings Snapshot
Associated Press · 57d ago
BC-Most Active Stocks
Associated Press · 62d ago
VivoSim Provides Financial and Listing Compliance Update
GlobeNewswire · 63d ago
BC-Most Active Stocks
Associated Press · 79d ago
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
InvestorsHub · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.